- Home
- SF vs SNN Comparison
SF vs SNN Comparison
Compare SF & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SF
- SNN
- Stock Information
- Founded
- SF 1890
- SNN 1856
- Country
- SF United States
- SNN United Kingdom
- Employees
- SF N/A
- SNN N/A
- Industry
- SF Investment Bankers/Brokers/Service
- SNN Industrial Specialties
- Sector
- SF Finance
- SNN Health Care
- Exchange
- SF Nasdaq
- SNN Nasdaq
- Market Cap
- SF 10.7B
- SNN 11.0B
- IPO Year
- SF N/A
- SNN 1999
- Fundamental
- Price
- SF $107.28
- SNN $24.44
- Analyst Decision
- SF Hold
- SNN Strong Buy
- Analyst Count
- SF 8
- SNN 1
- Target Price
- SF $105.57
- SNN N/A
- AVG Volume (30 Days)
- SF 592.5K
- SNN 719.7K
- Earning Date
- SF 01-22-2025
- SNN 08-01-2024
- Dividend Yield
- SF 1.57%
- SNN 3.06%
- EPS Growth
- SF 27.32
- SNN 39.77
- EPS
- SF 5.54
- SNN 0.35
- Revenue
- SF $4,715,429,000.00
- SNN $5,642,000,000.00
- Revenue This Year
- SF $16.79
- SNN $6.97
- Revenue Next Year
- SF $9.41
- SNN $5.46
- P/E Ratio
- SF $19.37
- SNN $35.34
- Revenue Growth
- SF 9.78
- SNN 5.48
- 52 Week Low
- SF $67.61
- SNN $23.65
- 52 Week High
- SF $119.12
- SNN $31.72
- Technical
- Relative Strength Index (RSI)
- SF 44.77
- SNN 32.06
- Support Level
- SF $101.75
- SNN $24.42
- Resistance Level
- SF $113.21
- SNN $25.70
- Average True Range (ATR)
- SF 2.71
- SNN 0.32
- MACD
- SF -0.96
- SNN -0.05
- Stochastic Oscillator
- SF 41.83
- SNN 1.28
About SF Stifel Financial Corporation
Stifel Financial is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 60% of the company's net revenue is derived from its global wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.